Compare RCAT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | IVA |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | RCAT | IVA |
|---|---|---|
| Price | $10.51 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $20.00 | $16.20 |
| AVG Volume (30 Days) | ★ 9.2M | 699.1K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,836,382.00 | N/A |
| Revenue This Year | $271.60 | N/A |
| Revenue Next Year | $41.21 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $3.35 |
| 52 Week High | $18.78 | $7.98 |
| Indicator | RCAT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 55.72 |
| Support Level | $7.16 | $4.11 |
| Resistance Level | $11.74 | $4.70 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | 0.37 | -0.01 |
| Stochastic Oscillator | 75.67 | 62.50 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.